Clinical Trial: Open-Label, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06941376) titled 'Open-Label, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis' on April 15.

Brief Summary: Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Relapsing Polychondritis

Intervention: DRUG: Methotrexate (MTX)

Weekly methotrexate dose of 20 mg (oral or subcutaneous).

DRUG: Azathioprine (AZA)

Azathioprine dose will be 2-3 mg/kg body weight per day.

BIOLOGICAL: Adalimumab

Adalimu...